Roche ends two Ionis-partnered Huntington's drugs after trial failures
Roche has discontinued two Huntington's disease therapies developed with Ionis Pharmaceuticals after one failed to slow disease progression and the second showed safety concerns in animal studies.
Read the full articleYou might also wanna read
Roche ends 2 Huntington’s disease programs, including Ionis-partnered tominersen
Roche has halted development on two of its Huntington’s disease prospects, marking another blow for a patient community that has long awaite
Roche abandons two Huntington's drug candidates
Roche abandons two Huntington's drug candidates Phil.Taylor Fri, 10/07/2026 - 08:43
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across
STAT+: Roche ends Huntington’s gene-silencing programs
ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout
AstraZeneca’s Wainua fails main goal in late-stage heart disease trial
Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems
STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drug
Comments
Sign in to join the conversation.
No comments yet. Be the first.